SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Estimated risk of transfusion‐transmitted viral infections in Spain
5 references·16 citing·38 second hop
Estimated risk of transfusion‐transmitted viral infections in Spain (2002)Estimated risk of transfusion‐transmitted…Results of Viral Marker Screening of Unpaid Blood Donations and Probability of Window Period Donations in 1997 (2000)Results of Viral Marker Scree…The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection (1997)The incidence/window period m…The Risk of Transfusion-Transmitted Viral Infections (1996)The Risk of Transfusion-Trans…Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States (1995)Estimated Risk of Transmissio…Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study (1995)Declining value of alanine am…Evolution of Blood Safety in Switzerland over the Last 25 Years for HIV, HCV, HBV and Treponema pallidum (2022)Evolution of Blood Safety in …Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the Region of Valencia, Spain, during a 15-year period (2003-2017). (2019)Evolution of the residual ris…Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil (2017)Residual risk of transmission…Seroprevalence of human immunodeficiency virus in north Indian blood donors using third and fourth generation Enzyme linked immunosorbent assay (2013)Seroprevalence of human immun…Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 2010 (2012)Residual risk of transfusion-…Evaluation of two, commercial, multi‐dye, nucleic acid amplification technology tests, for HBV/HCV/HIV‐1/HIV‐2 and B19V/HAV, for screening blood and plasma for further manufacture (2012)Evaluation of two, commercial…Seroprevalence Of Common Transfusion - Transmitted infections among Blood Donors (2010)Seroprevalence Of Common Tran…Trends in HIV prevalence in blood donations in Europe, 1990–2004 (2007)Trends in HIV prevalence in b…Detection of HIV‐1 infection in blood donors during the immunological window period using the nucleic acid‐amplification technology (2007)Detection of HIV‐1 infection …Transfusion Transmitted Infections in Armed Forces: Prevalence and Trends (2006)Transfusion Transmitted Infec…Safety of blood supply in the Caribbean countries: Role of screening blood donors for markers of hepatitis B and C viruses (2005)Safety of blood supply in the…Residual risk of transfusion‐transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy (2005)Residual risk of transfusion‐…Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations (2005)Multicenter performance evalu…Biological qualification of blood units (2004)Biological qualification of b…HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation (2003)HIV antibody screening remain…Health and economic impact of posttransfusion hepatitis B and cost‐effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union (2003)Health and economic impact of…Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases (2000)International application of the Incidence Rate/Window Period model (2002)Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window‐phase donations not detected by NAT (2002)Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations (2006)The Cambridge Ancient History (1971)Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA (2006)Evaluation of a multiplex human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand (2007)Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201 (2008)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)The risk of transfusion-transmitted viral infections at the Gabonese National Blood Transfusion Centre. (2014)Current State of Blood Management Services in Korea (2021)Transmission of Human Immunodeficiency Virus (HIV) by Blood Transfusions Screened as Negative for HIV Antibody (1988)Collection and transfusion of blood and blood components in the United States, 1994 (1998)Trends in Incidence and Prevalence of Major Transfusion-Transmissible Viral Infections in US Blood Donors, 1991 to 1996 (2000)Clinical Decision Analysis (1980)Donor Transaminase and Recipient Hepatitis (1981)EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURES (1998)Handling uncertainty when performing economic evaluation of healthcare interventions. (1999)Preference-Based Measures in Economic Evaluation in Health Care (2000)Clinical decision analysis (2005)Exposure of Patients to Human Immunodeficiency Virus through the Transfusion of Blood Components That Test Antibody-Negative (1989)Evaluation of Screened Blood Donations for Human Immunodeficiency Virus Type 1 Infection by Culture and DNA Amplification of Pooled Cells (1991)Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States (2004)Current incidence and estimated residual risk of transfusion‐transmitted infections in donations made to Canadian Blood Services (2007)Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting (1999)Residual risk of transfusion‐transmitted HCV and HIV infections by antibody‐screened blood in Italy (2002)Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions (2009)No evidence of a significantly increased risk of transfusion‐transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12‐month deferral for men who have had sex with men (CME) (2010)A convenient approximation of life expectancy (the “DEALE”) (1982)The Markov Process in Medical Prognosis (1983)Simulation modeling and analysis (1999)Seroepidemiologic Study of Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus and Syphilis Infections in Iranian Blood Donors (2007)Cost‐effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands (2008)Residual infectious disease risk in screened blood transfusion from a high‐prevalence population: Santa Catarina, Brazil (2007)Trends in prevalence, incidence, and residual risk of major transfusion‐transmissible viral infections in United Arab Emirates blood donors: impact of individual‐donation nucleic acid testing, 2004 through 2009 (2012)Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey. (2018)Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)
this work references cited by second hop

References

  • 1996The Risk of Transfusion-Transmitted Viral Infections1,865 cited
  • 1995Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States346 cited
  • 1997The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection168 cited
  • 1995Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study124 cited
  • 2000Results of Viral Marker Screening of Unpaid Blood Donations and Probability of Window Period Donations in 199777 cited

Cited by

  • 2005Residual risk of transfusion‐transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy57 cited
  • 2005Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations56 cited
  • 2012Residual risk of transfusion-transmitted infection with human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in Korea from 2000 through 201046 cited
  • 2003Health and economic impact of posttransfusion hepatitis B and cost‐effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union34 cited
  • 2004Biological qualification of blood units29 cited
  • 2012Evaluation of two, commercial, multi‐dye, nucleic acid amplification technology tests, for HBV/HCV/HIV‐1/HIV‐2 and B19V/HAV, for screening blood and plasma for further manufacture

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

27 cited
  • 2010Seroprevalence Of Common Transfusion - Transmitted infections among Blood Donors27 cited
  • 2006Transfusion Transmitted Infections in Armed Forces: Prevalence and Trends26 cited
  • 2017Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil25 cited
  • 2003HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation25 cited
  • 2019Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the Region of Valencia, Spain, during a 15-year period (2003-2017).24 cited
  • 2007Trends in HIV prevalence in blood donations in Europe, 1990–200417 cited
  • 2005Safety of blood supply in the Caribbean countries: Role of screening blood donors for markers of hepatitis B and C viruses16 cited
  • 2007Detection of HIV‐1 infection in blood donors during the immunological window period using the nucleic acid‐amplification technology13 cited
  • 2022Evolution of Blood Safety in Switzerland over the Last 25 Years for HIV, HCV, HBV and Treponema pallidum10 cited
  • 2013Seroprevalence of human immunodeficiency virus in north Indian blood donors using third and fourth generation Enzyme linked immunosorbent assay10 cited